Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers

Biochemical Journal

Volumn 436, Issue 3, 2011, Pages 671-679

  Zaremba, Tomasz ^a   Thomas, Huw D ^a   Cole, Michael ^a   Coulthard, Sally A ^a   Plummer, Elizabeth R ^a   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; DNA repair; Poly(ADP ribose) polymerase (PARP); Poly(ADP ribose) polymerase activity; Poly(ADP ribose) polymerase expression; Radiotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; ESTRADIOL VALERATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TAMOXIFEN; TEMOZOLOMIDE;

ADULT; ALLERGIC REACTION; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CASTRATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DYSPHAGIA; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHEMA; ESTROGEN THERAPY; ETHNICITY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; KIDNEY FAILURE; LETHARGY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOUSE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RADIATION INJURY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; TOXICITY; TREATMENT RESPONSE; VOMITING; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ENZYME ACTIVATION; ESTRADIOL; FEMALE; HUMANS; K562 CELLS; LEUKOCYTES, MONONUCLEAR; LIVER; MALE; MICE; MIDDLE AGED; NEOPLASMS; PHARMACOGENETICS; POLY(ADP-RIBOSE) POLYMERASES; POLYMORPHISM, GENETIC; SEX FACTORS;

MUS;

EID: 79957726564     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20101723     Document Type: Article

References (34)

1. Curtin, N. J. (2005) PARP inhibitors for cancer therapy. Expert Rev. Mol. Med. 7, 1-20
2. Jagtap, P. and Szabo, C. (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421-440
3. Virag, L. and Szabo, C. (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375-429
4. Lockett, K. L., Hall, M. C., Xu, J., Zheng, S. L., Berwick, M., Chuang, S. C., Clark, P. E., Cramer, S. D., Lohman, C. and Hu, J. J. (2004) The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res. 64, 6344-63448
5. Ranjit, G. B., Cheng, M. F., Mackay, W., Whitacre, C. M., Berger, J. S. and Berger, N. A. (1995) Poly(adenosine diphosphoribose) polymerase in peripheral blood leukocytes from normal donors and patients with malignancies. Clin. Cancer Res. 1, 223-234
6. Plummer, E. R., Middleton, M. R., Jones, C., Olsen, A., Hickson, I., McHugh, P., Margison, G. P., McGown, G., Thorncroft, M., Watson, A. J. et al. (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin. Cancer Res. 11, 3402-3409
7. Muiras, M. L., Muller, M., Schachter, F. and Burkle, A. (1998) Increased poly(ADP-ribose) polymerase activity in lymphoblastoid cell lines from centenarians. J. Mol. Med. 76, 346-354
8. Fougerousse, F., Meloni, R., Roudaut, C. and Beckmann, J. S. (1992) Dinucleotide repeat polymorphism at the human poly (ADP-ribose) polymerase gene (PPOL). Nucleic Acids Res. 20, 1166
9. Schweiger, M., Oei, S. L., Herzog, H., Menardi, C., Schneider, R., Auer, B. and Hirsch-Kauffmann, M. (1995) Regulation of the human poly(ADP-ribosyl) transferase promoter via alternative DNA racket structures. Biochimie 77, 480-485
10. Oei, S. L. and Shi, Y. (2001) Poly(ADP-ribosyl)ation of transcription factor Yin Yang 1 under conditions of DNA damage. Biochem. Biophys. Res. Commun. 285, 27-31
11. Oei, S. L. and Shi, Y. (2001) Transcription factor Yin Yang 1 stimulates poly(ADP-ribosyl)ation and DNA repair. Biochem. Biophys. Res. Commun. 284, 450-454
12. Zhang, X., Miao, X., Liang, G., Hao, B., Wang, Y., Tan, W., Li, Y., Guo, Y., He, F., Wei, Q. and Lin, D. (2005) Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res. 65, 722-726 (Pubitemid 40216429)
13. Wang, X. G., Wang, Z. Q., Tong, W. M. and Shen, Y. (2007) PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem. Biophys. Res. Commun. 354, 122-126
14. Chiang, F. Y., Wu, C. W., Hsiao, P. J., Kuo, W. R., Lee, K. W., Lin, J. C., Liao, Y. C. and Juo, S. H. (2008) Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin. Cancer Res. 14, 5919-5924
15. Beneke, S., Scherr, A. L., Ponath, V., Popp, O. and Burkle, A. (2010) Enzyme characteristics of recombinant poly(ADP-ribose) polymerases-1 of rat and human origin mirror the correlation between cellular poly(ADP-ribosyl)ation capacity and species-specific life span. Mech. Ageing Dev. 131, 366-369
16. Grube, K. and Burkle, A. (1992) Poly(ADP-ribose) polymerase activity in mononuclear leukocytes of 13 mammalian species correlates with species-specific life span. Proc. Natl. Acad. Sci. U.S.A. 89, 11759-11763
17. Strosznajder, J. B., Jesko, H. and Strosznajder, R. P. (2000) Age-related alteration of poly(ADP-ribose) polymerase activity in different parts of the brain. Acta Biochim. Pol. 47, 331-337
18. Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D. et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923
19. Melisi, D., Ossovskaya, V., Zhu, C., Rosa, R., Ling, J., Dougherty, P. M., Sherman, B. M., Abbruzzese, J. L. and Chiao, P. J. (2009) Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin. Cancer Res. 15, 6367-6377
20. Zaremba, T., Ketzer, P., Cole, M., Coulthard, S., Plummer, E. R. and Curtin, N. J. (2009) Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br. J. Cancer 101, 256-262
21. Cottet, F., Blanche, H., Verasdonck, P., Le Gall, I., Schachter, F., Burkle, A. and Muiras, M. L. (2000) New polymorphisms in the human poly(ADP-ribose) polymerase-1 coding sequence: lack of association with longevity or with increased cellular poly(ADP-ribosyl)ation capacity. J. Mol. Med. 78, 431-440
22. Mohrenweiser, H. W., Xi, T., Vazquez-Matias, J. and Jones, I. M. (2002) Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol. Biomarkers Prev. 11, 1054-1064
23. Durocher, F., Labrie, Y., Ouellette, G. and Simard, J. (2007) Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. J. Hum. Genet. 52, 963-977
24. Pascual, M., Lopez-Nevot, M. A., Caliz, R., Ferrer, M. A., Balsa, A., Pascual-Salcedo, D. and Martin, J. (2003) A poly(ADP-ribose) polymerase haplotype spanning the promoter region confers susceptibility to rheumatoid arthritis. Arthritis Rheum. 48, 638-641 (Pubitemid 36301998)
25. Mabley, J. G., Horvath, E. M., Murthy, K. G., Zsengeller, Z., Vaslin, A., Benko, R., Kollai, M. and Szabó, C. (2005) Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J. Pharmacol. Exp. Ther. 315, 812-820
26. Szabo, C., Pacher, P. and Swanson, R. A. (2006) Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol. Sci. 27, 626-630
27. Yuan, M., Siegel, C., Zeng, Z., Li, J., Liu, F. and McCullough, LD. (2009) Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp. Neurol. 217, 210-218
28. Vagnerova, K., Liu, K., Ardeshiri, A., Cheng, J., Murphy, S. J., Hurn, P. D. and Herson, P. S. (2010) Poly (ADP-ribose) polymerase-1 initiated neuronal cell death pathway - do androgens matter? Neuroscience 166, 476-481
29. Charron, M. J. and Bonner-Weir, S. (1999) Implicating PARP and NAD+ depletion in type I diabetes. Nat. Med. 5, 267-270
30. Naugler, W. E., Sakurai, T., Kims, S., Maeda, S., Kim, K., Elsharkawy, A. M. and Karin, M. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (Pubitemid 47056470)
31. Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C. et al. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519
32. Sarkar, S. K., Patra, N. B., Goswami, J. and Basu, S. (2008) Comparative study of efficacy and toxicities of cisplatin vs vinorelbine as radiosensitisers in locally advanced head and neck cancer. J. Laryngol. Otol. 122, 188-192
33. Dimopoulou, I., Efstathiou, E., Samakovli, A., Dafni, U., Moulopoulos, L. A., Papadimitriou, C., Lyberopoulos, P., Kastritis, E., Roussos, C. and Dimopoulos, M. A. (2004) A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann. Oncol. 15, 1250-1255
34. Goldberg, S. L., Chiang, L., Selina, N. and Hamarman, S. (2004) Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies. Support Care Cancer 12, 526-530 (Pubitemid 38931686)